These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2004-001116-31 Multicentre, randomised, double-blind, parallel group confirmatory Phase III study to compare the efficacy and safety of cizolirtine citrate 300 mg bid (600 mg/d), cizolirtine citrate 400 mg bid (800... 2004-12-21 due-trials
Ongoing 2004-001119-69 An evaluation of the dose-response relationship of Cizolirtine citrate 300 mg, twice daily, and 400 mg, twice daily, versus placebo in subjects with urge urinary incontinence. A 12-week, randomised, d... not-yet-due
Not reported 2005-000107-33 A 12-week multicentre, randomised, double-blind, parallel group, Phase II pilot study to evaluate the efficacy and safety of cizolirtine citrate 200 mg bid (400 mg/d), cizolirtine citrate 300 mg bid (... 2006-03-23 due-trials
Reported results 2005-000206-31 A randomized, placebo-controlled, double-blind Phase III study of the efficacy and safety of recombinant human C1 inhibitor for the treatment of acute attacks in patients with hereditary angioedema 2009-10-13 due-trials
Exempt, with results 2010-020343-13 A double-blind, randomised, placebo-controlled, 4‑way cross-over Phase I study to investigate the pharmacokinetics, pharmacodynamics and safety of escalating single doses of E‑52862 in young healthy m... 2010-08-12 not-yet-due
Reported results 2011-002778-21 A randomized, double-blind, controlled with active treatment (tramadol 100 mg) and placebo, parallel groups, Phase II clinical trial to establish the effective dose between 4 strengths of E-58425 for ... 2013-02-13 due-trials
Reported results 2011-003302-24 An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, as part of an analgesic the... 2013-09-26 due-trials
Reported results 2012-000398-21 A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence and ... 2014-12-23 due-trials
Completed, but no date, and reported results Terminated 2012-000399-41 An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with postherpet... bad-data
Reported results 2012-000400-14 An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with painful di... 2014-12-04 due-trials
Completed, but no date, and reported results 2012-000402-30 An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with post-surgi... bad-data
Ongoing 2015-000359-26 Phase I/II safety, tolerability and initial efficacy study of adeno-associated viral vector serotype 9 containing human sulfamidase gene after intracerebroventricular administration to patients with M... not-yet-due

Related organisations

Over time organisations can merge, or split.

We think Esteve is now also responsible for the trials of: